Figure 1From: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumorsImmunohistochemical staining of primary breast tumors. (a) Moderate-intensity membranous pHER1. (b) Strong-intensity membranous pHER2. (c) Moderate-intensity membranous pHER3. (d) Nuclear pHER3. (e) Moderate HER4 intensity. (f) Strong HER4 intensity.Back to article page